302 related articles for article (PubMed ID: 31503216)
1. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
[TBL] [Abstract][Full Text] [Related]
2. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
[TBL] [Abstract][Full Text] [Related]
3. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
[TBL] [Abstract][Full Text] [Related]
5. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
6. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
7. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK
Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692
[TBL] [Abstract][Full Text] [Related]
8. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
Franca R; Curci D; Lucafò M; Decorti G; Stocco G
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
[No Abstract] [Full Text] [Related]
10. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
[TBL] [Abstract][Full Text] [Related]
12. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease.
Thomas PWA; Chin PKL; Barclay ML
Intern Med J; 2021 Mar; 51(3):341-347. PubMed ID: 32043746
[TBL] [Abstract][Full Text] [Related]
13. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.
Morris GA; McNicol M; Boyle B; Donegan A; Dotson J; Michel HK; Maltz RM
Inflamm Bowel Dis; 2022 Mar; 28(4):531-538. PubMed ID: 34037215
[TBL] [Abstract][Full Text] [Related]
14. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
[TBL] [Abstract][Full Text] [Related]
15. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
16. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
17. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
[TBL] [Abstract][Full Text] [Related]
18. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Samaan MA; Arkir Z; Ahmad T; Irving PM
Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
Gofin Y; Matar M; Shamir R; Assa A
Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
